adenosine has been researched along with Stroke in 99 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 15 (15.15) | 29.6817 |
2010's | 76 (76.77) | 24.3611 |
2020's | 8 (8.08) | 2.80 |
Authors | Studies |
---|---|
Heleä, JJ; Järvelä, KM; Laurikka, JO; Mattila, MS; Nikus, KC; Rantanen, MJ; Rinne, TT; Siltanen, JAA | 1 |
Chen, YS; Hsieh, ST; Wang, YC | 1 |
Feng, J; Hao, M; Jiang, C; Li, Q; Ling, Y; Liu, F; Shang, X; Wang, B; Xiao, Z; Zhao, H; Zhao, N | 1 |
Bai, Y; Bian, L; Chao, J; Gu, X; Han, B; Li, B; Li, L; Liu, C; Liu, X; Shen, L; Tang, Y; Wang, J; Wang, Y; Xi, W; Xie, J; Yang, L; Yao, H; Yu, X; Zhang, Y; Zhou, Z | 1 |
Chen, Y; Han, W; Tian, Y; Wang, S; Zhang, E | 1 |
Borea, PA; Casetta, I; Gessi, S; Laudisi, M; Merighi, S; Pasquini, S; Varani, K; Vincenzi, F | 1 |
Boland, P; Chong, AY; Di Santo, P; Froeschl, M; Gaudet, C; Hibbert, B; Joseph, J; Jung, RG; Labinaz, A; Le May, M; Marbach, J; Moreland, R; Motazedian, P; Parlow, S; Promislow, S; Ramirez, FD; Russo, JJ; Simard, T; So, D | 1 |
Angiolillo, D; Birnbaum, Y; Khawaja, M; Kherallah, RY; Olson, M | 1 |
Cao, Y; Chen, G; Chen, W; Li, H; Li, J; Li, X; Lin, Y; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Wang, Z; Wu, J; Xu, Y; Zhang, G; Zhao, X | 1 |
Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J | 1 |
Hua, YH; Li, JN; Liu, C; Liu, J; Song, L; Tan, Y; Wu, Y; Yan, HB; Yang, YM; Zhao, HJ; Zhou, P | 1 |
Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 1 |
Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL | 1 |
Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 2 |
Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, DJ; Cohen, M; Li, H; Magnuson, EA; Sabatine, MS; Shafiq, A; Steg, PG; Storey, RF; Vilain, K; Wang, K | 1 |
Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
Al-Salama, ZT; Keam, SJ; Keating, GM | 1 |
He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
Baumgartner, I; Berger, JS; Björck, M; Blomster, JI; Fowkes, FGR; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Norgren, L; Patel, MR; Rockhold, FW; Wojdyla, DM | 1 |
Abe, T; Elkordy, A; Mishima, E; Niizuma, K; Rashad, S; Shehabeldeen, H; Tominaga, T | 1 |
Lei, SF; Mo, XB; Zhang, H; Zhang, YH | 1 |
Himi, N; Itano, T; Maruyama, T; Miyamoto, O; Nakamura, E; Nakamura, T; Narita, K; Okabe, N; Sakakibara, N; Tsukamoto, I | 1 |
Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 2 |
DiNicolantonio, JJ; Serebruany, VL | 1 |
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
Aylward, P; Brandrup-Wognsen, G; Brilakis, ES; Claeys, MJ; Cools, F; Cornel, JH; Held, C; Himmelmann, A; James, SK; Lewis, BS; Meier, B; Stevens, SR; Wallentin, L; Weaver, D | 1 |
Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
Hartmark-Hill, JR; Tsang, K | 1 |
Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B | 1 |
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
Abbracchio, MP; Cimino, M; Enerbäck, M; Fumagalli, M; Gelosa, P; Lecca, D; Nikookhesal, E; Pignieri, A; Sironi, L; Tremoli, E; Verderio, C; Wypych, D | 1 |
Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
Lindquist, BE; Shuttleworth, CW | 1 |
Gaussem, P; Godier, A; Taylor, G | 1 |
Ducruet, AF; Faraji, AH; Weiner, GM | 1 |
Burnstock, G | 1 |
Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
Abunassar, J; Chong, AY; Dick, A; Froeschl, M; Fu, A; Glover, C; Hibbert, B; Labinaz, M; Le May, M; Malhotra, N; Marquis, JF; Singh, K; So, DY | 1 |
Jing, Q; Li, R; Liu, P; Liu, Y; Tang, X; Wang, Q; Zhang, P | 1 |
Angiolillo, DJ; Bansilal, S; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Im, K; Murphy, SA; Sabatine, MS; Steg, PG; Storey, RF | 1 |
Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF | 1 |
Biby, S; Campbell, BC; Lo, KY; Sethi, P | 1 |
Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS | 2 |
Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C | 1 |
Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
Anstrom, K; Bhandary, DD; Cannon, CP; Choudhry, NK; Cohen, DJ; Davidson-Ray, LD; Doll, JA; Fonarow, GC; Henry, TD; Khan, N; Peterson, ED; Wang, TY | 1 |
Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
Ding, Y; Geng, X; Khan, H; Liu, K; Zhang, J | 1 |
Chung, SC; Denaxas, S; Emmas, C; Hemingway, H; Moayyeri, A; Pasea, L; Pujades-Rodriguez, M; Rapsomaniki, E; Shah, AD; Stogiannis, D; Timmis, A | 1 |
Aylward, PE; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dalby, AJ; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Kontny, F; Kuder, J; Magnani, G; Medina, FA; Oude Ophuis, T; Sabatine, MS; Špinar, J; Steg, PG; Storey, R; Theroux, P | 1 |
Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
Priglinger, ML | 1 |
Holmes, D | 1 |
Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF | 1 |
Attmann, T; Beyersdorf, F; Boening, A; Cremer, J; Danner, BC; de Waha, A; Fischlein, T; Goerlach, G; Hambrecht, R; Hamm, C; Hammel, D; Joost, A; Kastrati, A; Knosalla, C; Koch-Buettner, K; Lange, R; Laufer, G; Misfeld, M; Mohr, FW; Oberhoffer, M; Putman, LM; Radke, PW; Sandner, S; Schmoeckel, M; Schöndube, FA; Schönrath, F; Schulz, R; Schunkert, H; Siepe, M; Sievers, HH; von Scheidt, M; Walther, T; Zeymer, U; Ziegelhöffer, T | 1 |
Alexopoulos, D; Lekakis, J; Moulias, A; Xanthopoulou, I | 1 |
Avgerinos, E; Bakoyiannis, C; Moris, D | 1 |
Johnston, SC; Wang, Y | 1 |
Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
Collet, JP; Montalescot, G | 1 |
Atar, D; Serebruany, VL | 2 |
Cattaneo, M | 1 |
Komai, M; Koseki, T; Shirakawa, H; Sugita, Y | 1 |
Easton, JD | 1 |
Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
Calvi, V; Capodanno, D; Tamburino, C | 1 |
Angiolillo, DJ; Cannon, CP; Cantor, WJ; Clare, R; Goodman, SG; Harrington, RA; Husted, S; James, SK; Kilhamn, J; Mahaffey, KW; Nicolau, JC; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
Serebruany, VL | 2 |
Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
Verheugt, FW | 1 |
Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
Anderson, RD; Azarbal, B; Handberg, E; Johnson, BD; Kar, S; Kelsey, SF; Kothawade, K; Lerman, A; Mehta, PK; Merz, CN; Pepine, CJ; Petersen, J; Samuels, B; Sharaf, B; Shaw, L; Shufelt, C; Sopko, G; Wei, J | 1 |
Ambrosio, G; Ferguson, TB; Harrington, RA; Koglin, J; Lira, A; Newman, MF; Nussmeier, NA; Pearl, RG; Pitt, B; Reece, TL; Wechsler, AS; Weisel, RD; White, JA | 1 |
Fort, JG; Plachetka, JR | 1 |
Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
Bernhardt, P; Buckert, D; Dewes, P; Rottbauer, W; Walcher, T | 1 |
Danton, G; Dietric, WD; Prado, R; Watson, BD | 1 |
Schaper, W | 1 |
Kennedy, TP; Vinten-Johansen, J | 1 |
Boison, D | 1 |
Capone, C; Girouard, H; Iadecola, C; Lessard, A; Milner, TA | 1 |
Setarehbadi, R; Sheikh, N; Tavilani, H; Vaisi-raygani, A | 1 |
Fricker, J | 1 |
Di Perri, T; Guideri, F; Laghi Pasini, F; Parenti, G; Petersen, C; Picano, E; Varga, A | 1 |
Bergmann, SR | 1 |
von Lubitz, DK | 1 |
Lin, RC; Simpson, KL; Von Lubitz, DK | 1 |
Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M | 1 |
20 review(s) available for adenosine and Stroke
Article | Year |
---|---|
Cilostazol: a Review of Basic Mechanisms and Clinical Uses.
Topics: Adenosine; Cilostazol; Humans; Intermittent Claudication; Platelet Aggregation Inhibitors; Stroke; Tetrazoles | 2022 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure | 2017 |
Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.
Topics: Adenosine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor | 2017 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Drug Administration Schedule; Drug Costs; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; United States | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration.
Topics: Adenosine; Animals; Brain; Brain Ischemia; Humans; Nerve Regeneration; Neural Stem Cells; Neurodegenerative Diseases; Neurons; Purines; Pyrimidines; Receptors, Purinergic; Receptors, Purinergic P2X; Receptors, Purinergic P2Y; Signal Transduction; Stroke | 2016 |
Pharmacological hypothermia: a potential for future stroke therapy?
Topics: Adenine Nucleotides; Adenosine; Animals; Cannabinoids; Humans; Hypothermia; Hypothermia, Induced; Neuroprotective Agents; Neurotensin; Receptors, Dopamine; Receptors, Opioid; Stroke; Thyroxine; TRPV Cation Channels | 2016 |
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients: Facing a New Trilemma?
Topics: Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Antithrombotic management for transient ischemic attack and ischemic stroke (other than atrial fibrillation).
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Fibrinolytic Agents; Foramen Ovale, Patent; Genotype; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Endothelium-targeted pharmacotherapeutics for the treatment of stroke.
Topics: Adenosine; Animals; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Endothelium, Vascular; Free Radical Scavengers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase Inhibitors; Serotonin Antagonists; Stroke; Vasodilator Agents | 2002 |
Dipyridamole, an underestimated vascular protective drug.
Topics: Adenosine; Angina Pectoris; Animals; Atherosclerosis; Coronary Circulation; Coronary Vessels; Dipyridamole; Heart; Humans; Myocardium; Nucleoside Transport Proteins; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Vasodilator Agents | 2005 |
A review of the clinical use of anti-inflammatory therapies for reperfusion injury in myocardial infarction and stroke: where do we go from here?
Topics: Adenosine; Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Myocardial Infarction; Myocardial Reperfusion Injury; Stroke; Vasodilator Agents | 2006 |
Adenosine kinase, epilepsy and stroke: mechanisms and therapies.
Topics: Adenosine; Adenosine Kinase; Animals; Brain; Drug Delivery Systems; Enzyme Inhibitors; Epilepsy; Humans; Stroke | 2006 |
Adenosine in the treatment of stroke: yes, maybe, or absolutely not?
Topics: Adenosine; Brain Ischemia; Humans; Phosphatidylinositols; Receptors, Purinergic P1; Stroke | 2001 |
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Occlusive Diseases; Cell Division; Cilostazol; Coronary Restenosis; Coronary Thrombosis; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Fibrinolytic Agents; Humans; Hypolipidemic Agents; Muscle, Smooth, Vascular; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Vasodilator Agents | 2001 |
32 trial(s) available for adenosine and Stroke
Article | Year |
---|---|
High-dose adenosine versus saline-induced cardioplegic arrest in coronary artery bypass grafting: A randomized double-blind clinical feasibility trial.
Topics: Adenosine; Coronary Artery Bypass; Feasibility Studies; Heart Arrest; Heart Arrest, Induced; Humans; Nucleosides; Potassium; Stroke | 2022 |
Effect of ticagrelor with clopidogrel on high on-treatment platelet reactivity in acute stroke or transient ischemic attack (PRINCE) trial: Rationale and design.
Topics: Adenosine; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Heterozygote; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial.
Topics: Adenosine; Aged; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2017 |
Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial.
Topics: Adenosine; Aged; Clopidogrel; Female; Hospitalization; Humans; Hypertension; Incidence; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Lower Extremity; Male; Middle Aged; Peripheral Arterial Disease; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome; Vascular Surgical Procedures | 2018 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Survival Analysis; Ticagrelor; Treatment Outcome | 2013 |
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Topics: Adenosine; Aged; Chi-Square Distribution; China; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.
Topics: Adenosine; Aged; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor; Vascular Grafting | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2016 |
Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial.
Topics: Adenosine; Aged; Ankle Brachial Index; Clopidogrel; Disease Progression; Female; Humans; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction.
Topics: Adenosine; Clopidogrel; Cost Sharing; Drug Costs; Financial Support; Health Care Costs; Health Expenditures; Humans; Logistic Models; Medication Adherence; Mortality; Multivariate Analysis; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.
Topics: Adenosine; Dyspnea; Hemorrhage; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Quality of Life; Secondary Prevention; Stroke; Ticagrelor | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Stroke; Ticagrelor | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2016 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Topics: Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial.
Topics: Adenosine; Aged; Aminoimidazole Carboxamide; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Perioperative Period; Reperfusion Injury; Ribonucleosides; Stroke; Ventricular Dysfunction, Left | 2012 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
47 other study(ies) available for adenosine and Stroke
Article | Year |
---|---|
Neuroprotective Effects of a Cardioplegic Combination (Adenosine, Lidocaine, and Magnesium) in an Ischemic Stroke Model.
Topics: Adenosine; Animals; Cardioplegic Solutions; Cobalt; Disease Models, Animal; Glucose; Humans; Ischemic Stroke; Lidocaine; Magnesium; Neuroblastoma; Neuroprotective Agents; Oxygen; Rats; Stroke | 2022 |
Serum adenosine deaminase activity and acute cerebral infarction: a retrospective case-control study based on 7913 participants.
Topics: Adenosine; Adenosine Deaminase; Brain Ischemia; Case-Control Studies; Cerebral Infarction; Humans; Retrospective Studies; Stroke | 2022 |
FTO-dependent m
Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Animals; Endothelial Cells; Infarction; Male; Mice; Phosphatidate Phosphatase; RNA, Circular; RNA, Messenger; Stroke | 2023 |
Adenosine receptor A1 enhanced mitochondrial biogenesis and exerted neuroprotection after cerebral ischemia through PGC-1α.
Topics: Adenosine; Animals; Brain Ischemia; Ischemic Stroke; Mice; Neuroprotection; Organelle Biogenesis; Receptors, Purinergic P1; Stroke | 2023 |
Adenosinergic System Involvement in Ischemic Stroke Patients' Lymphocytes.
Topics: 5'-Nucleotidase; Adenosine; Aged; Aged, 80 and over; Antigens, CD; Apyrase; Brain Ischemia; Female; GPI-Linked Proteins; Humans; Ischemic Stroke; Lymphocytes; Male; Membrane Proteins; Phosphoproteins; Receptors, Purinergic P1; Stroke | 2020 |
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk.
Topics: Adenosine; Aged; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Heart Disease Risk Factors; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Registries; Risk Assessment; Stroke | 2021 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2017 |
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
tiRNAs as a novel biomarker for cell damage assessment in in vitro ischemia-reperfusion model in rat neuronal PC12 cells.
Topics: Adenosine; Animals; Biomarkers; Cell Survival; Glucose; Hypoxia; Ischemia; Neurons; Oxygen; PC12 Cells; Rats; Reperfusion Injury; Ribonuclease, Pancreatic; RNA, Transfer; Stress, Physiological; Stroke | 2019 |
Examination of the associations between m
Topics: Adenosine; Blood Pressure; Coronary Artery Disease; Genome-Wide Association Study; Homeodomain Proteins; Humans; Polymorphism, Single Nucleotide; Qb-SNARE Proteins; Stroke | 2019 |
Delayed administration of the nucleic acid analog 2Cl-C.OXT-A attenuates brain damage and enhances functional recovery after ischemic stroke.
Topics: Adenosine; Animals; Blotting, Western; Cerebrovascular Circulation; Disease Models, Animal; Immunohistochemistry; In Situ Nick-End Labeling; Male; MAP Kinase Signaling System; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Recovery of Function; Stroke | 2013 |
Letter by Serebruany and DiNicolantonio regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor.
Topics: Adenosine; Animals; Brain Ischemia; Chemokine CCL2; Ectodysplasins; Fibrinolytic Agents; Interleukin-1; Mice; Mice, Transgenic; Microglia; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Stroke; Ticagrelor; Time Factors | 2014 |
Spreading depolarization-induced adenosine accumulation reflects metabolic status in vitro and in vivo.
Topics: Adenosine; Animals; Biomarkers; Brain; Brain Ischemia; Cortical Spreading Depression; Mice; Stroke | 2014 |
Inefficacy of platelet transfusion to reverse ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antidotes; Fatal Outcome; Humans; Male; Platelet Count; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2015 |
The use of nanotechnology to improve the neuroprotective effects of adenosine in stroke and spinal cord injury.
Topics: Adenosine; Animals; Drug Delivery Systems; Humans; Male; Nanoparticles; Nanotechnology; Neuroprotective Agents; Spinal Cord Injuries; Squalene; Stroke | 2015 |
Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications.
Topics: Adenosine; Chi-Square Distribution; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Symptomatic intracerebral and systemic hemorrhage after stroke thrombolysis in patients taking ticagrelor.
Topics: Adenosine; Aged; Female; Fibrinolytic Agents; Hemorrhage; Humans; Stroke; Thrombolytic Therapy; Ticagrelor; Tissue Plasminogen Activator | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Electronic Health Records; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2016 |
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days.
Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2016 |
Bone: Antiplatelet agent promotes bone formation.
Topics: Adenosine; Bone and Bones; Humans; Osteogenesis; Platelet Aggregation Inhibitors; Stroke | 2016 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Anti-metabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenosine; Adiponectin; Adipose Tissue; Animals; Antioxidants; Blood Glucose; Cardiovascular Agents; Deoxyguanosine; Dietary Fats; Enzymes; Gene Expression; Gene Expression Regulation; Hypertension; Insulin; Kidney; Lipids; Liver; Male; Metabolic Syndrome; Nitric Oxide; Rats; Rats, Inbred SHR; Receptors, Adiponectin; RNA, Messenger; Stroke | 2010 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Humans; Multicenter Studies as Topic; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine | 2012 |
Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study.
Topics: Acetylcholine; Adenosine; Adult; Blood Flow Velocity; Coronary Angiography; Coronary Circulation; Coronary Vessels; Female; Heart Failure; Hospitalization; Humans; Laser-Doppler Flowmetry; Microcirculation; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Nitroglycerin; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Stroke; United States; Vasodilator Agents | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
Letter by Fort and Plachetka regarding article, "association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from PLATO".
Topics: Adenosine; Female; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Stroke; Ticlopidine | 2012 |
Intermediate-term prognostic value of reversible perfusion deficit diagnosed by adenosine CMR: a prospective follow-up study in a consecutive patient population.
Topics: Adenosine; Aged; Angina, Stable; Chi-Square Distribution; Contrast Media; Coronary Circulation; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Time Factors; Vasodilator Agents | 2013 |
The neurovascular dysfunction induced by angiotensin II in the mouse neocortex is sexually dimorphic.
Topics: Acetylcholine; Adenosine; Angiotensin II; Animals; Blood Flow Velocity; Blood Pressure; Cerebrovascular Circulation; Disease Models, Animal; Disease Susceptibility; Estradiol; Estrogen Replacement Therapy; Female; Hypertension; Infusion Pumps, Implantable; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Neocortex; Ovariectomy; Reflex; Sex Factors; Stroke; Time Factors; Vasodilator Agents; Vibrissae | 2008 |
Sex differences in adenosine deaminase activity of stroke patients.
Topics: Adenosine; Adenosine Deaminase; Aged; Blood Chemical Analysis; Female; Humans; Inosine; Ischemia; Male; Middle Aged; Risk Factors; Sex Characteristics; Sex Factors; Stroke; Time Factors | 2008 |
Unravelling adenosine's effects on stroke.
Topics: Adenosine; Animals; Brain Ischemia; Gene Deletion; Glutamic Acid; Humans; Mice; Mice, Knockout; Neurodegenerative Diseases; Neuroprotective Agents; Phenotype; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P1; Stroke | 2000 |
Increase in plasma adenosine during brain ischemia in man: a study during transient ischemic attacks, and stroke.
Topics: Adenosine; Aged; Female; Humans; Ischemic Attack, Transient; Male; Stroke | 2000 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemia; Platelet Aggregation Inhibitors; Stroke; Vasodilator Agents | 2001 |
Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke.
Topics: Adenosine; Animals; Brain; Brain Ischemia; Male; Mice; Neurons; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Receptors, Purinergic P1; Stroke | 2001 |